Publication Name	World Journal of Diabetes
Manuscript ID	90155
Country	China

Received	2023-11-25 08:28
Peer-Review Started	2023-11-25 08:30
First Decision by Editorial Office Director	2023-12-12 07:31
Return for Revision	2023-12-12 07:31
Revised	2023-12-14 01:54
Publication Fee Transferred
Second Decision by Editor	2024-01-05 02:02
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-01-16 05:20
Articles in Press	2024-01-16 05:20
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-01-29 17:22
Publish the Manuscript Online	2024-02-04 10:57

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control
Manuscript Source	Invited Manuscript
All Author List	Ke-Xin Zhang, Cheng-Xia Kan, Fang Han, Jing-Wen Zhang and Xiao-Dong Sun
ORCID	Author(s) ORCID Number Ke-Xin Zhang http://orcid.org/0000-0002-9224-9465 Cheng-Xia Kan http://orcid.org/0000-0002-4593-0303 Fang Han http://orcid.org/0000-0002-8743-8763 Jing-Wen Zhang http://orcid.org/0000-0002-6064-1374 Xiao-Dong Sun http://orcid.org/0000-0001-7775-2823
Funding Agency and Grant Number
Corresponding Author	Xiao-Dong Sun, PhD, Chief Physician, Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, No. 2428 Yuhe Road, Weifang 261031, Shandong Province, China. xiaodong.sun@wfmc.edu.cn
Key Words	Diabetes; Sodium-glucose cotransporter-2; Cardiovascular diseases; Empagliflozin
Core Tip	Sodium-glucose cotransporter-2 (SGLT2) inhibitors like empagliflozin offer cardioprotective benefits that extend beyond blood glucose control, improving heart function and reducing failure-related hospitalizations. Ongoing research is essential to elucidate the underlying mechanisms, potentially revolutionizing heart failure treatment across various patient profiles.
Publish Date	2024-02-04 10:57
Citation	Zhang KX, Kan CX, Han F, Zhang JW, Sun XD. Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control. World J Diabetes 2024; 15(2): 137-141
URL	https://www.wjgnet.com/1948-9358/full/v15/i2/137.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i2.137

Full Article (PDF)	WJD-15-137-with-cover.pdf
Full Article (Word)	WJD-15-137.docx
Manuscript File	90155_Auto_Edited-YJP.docx
Answering Reviewers	90155-Answering reviewers.pdf
Audio Core Tip	90155-Audio core tip.wav
Conflict-of-Interest Disclosure Form	90155-Conflict-of-interest statement.pdf
Copyright License Agreement	90155-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90155-Language certificate.pdf
Peer-review Report	90155-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	90155-Journal editorial board’s review report.pdf
Scientific Misconduct Check	90155-CrossCheck.png
Scientific Misconduct Check	90155-Bing-Gong ZM-2.png
Scientific Editor Work List	90155-Scientific editor work list.pdf
CrossCheck Report	90155-CrossCheck report.pdf